The appearance of the COVID-19 pandemic caused by the SARS-CoV-2 virus tested the global ability to respond to broadly circulated diseases, enhancing the development, production, and approval in a record time of vaccines generated in a wide variety of platforms.
Facing the need for antigens supply for the Republic of Argentina in case of new pandemics, local outbreaks, and endemic diseases, Sinergium Biotech S.A. is working on the development of vaccines from innovative platforms.
At one end, the company focused on the incorporation of technologies for the manufacturing of recombinant vaccines derived from the system of expression of baculovirus in insect cells. Sinergium Biotech Development and Innovation Lab have achieved to set its own platform for the manufacturing of recombinant antigens using such technology.
In 2021, World Health Organization (WHO) appointed Sinergium Biotech –together with other leading institutions in biotechnology from America and Africa- to create a technological center for mRNA vaccine production. The aim of this program is to set up a state-of-the-art technology platform in low or medium-income countries. During the pandemic, mRNA vaccines have proven to reach the highest efficiency values in controlled clinical trials. Besides, it is not only interesting for sanitary purposes but also for the industry area considering its high productivity and short production times, among other qualities.
As part of this program, Sinergium has been trained in renowned institutions such as Afrigen Biologics & Vaccines, located in South Africa, The mRNA vaccine technology transfer hub, from WHO, and the Universidad de Buenos Aires (UBA).
On the other end, for some years now, Sinergium Biotech uses the Innovación Abierta (Open Innovation) strategy, in which innovative ideas come from within and outside the company. In such context, there were performed different agreements with important local universities of Argentina, such as UBA (Universidad de Buenos Aires), UNSAM (Universidad Nacional de San Martín), and UNLP (Universidad Nacional de La Plata), and institutes such as INTA (Instituto Nacional de Tecnología Agropecuaria) for the development of projects directed to new vaccines with recombining baculovirus technology and expression in insect cells. These projects aim to fight different illnesses such as yellow fever, Argentine hemorrhagic fever, chikungunya, and rabies.
Besides, Sinergium Biotech’s participation for many years now in the Argentine Chamber of Biotechnology joins the generation of innovative ideas and the coordination of valuable joint work between the Science and Technology key players of this country.
At present, we are planning to open a new call for allowing us to widen our areas of knowledge and to keep enriching public-private relations.